Anyone else think Monil Shah renumeration is a bit rich..?
He gets $190K bonus for signing a pre clinical partnership for OnCARlytic's. That was it to meet his KPI.
Current T cell therapy can only go after blood cancers. I cant see the difficultly or "work" required to get a partner for mouse models on solid tumours. And correct me if I am wrong, but aren't we covering our own costs in this partnership?
Given his $595K static salary. In my opinion if he hasn't generated any revenue for the company he should not be inline to receive a bonus.
He's also paid in a fixed USD amount. If the Ozzie tumbles he'll end up getting more then Leslie at this rate.
Hate to think what his bonus would be if he actually signs a commercial deal.
Ann: Annual Report to shareholders, page-30
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $400.5M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.4¢ | $361.8K | 6.583M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 3674962 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 123415 | 9 |
View Market Depth
| Last trade - 15.11pm 29/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |